BrainsWay announced a strategic minority-stake investment in Hopemark Health as part of its broader strategy to expand awareness of and access to advanced interventional psychiatry treatments across North America.
Under the terms of the agreement, BrainsWay entered into a strategic equity financing arrangement with APS Innovations LLC, the parent company of Advanced Psychiatric Management LLC, which services multiple mental health clinics in the greater Chicago area under the Hopemark Health brand. BrainsWay will invest an initial $1.5 million, with the potential to invest an additional $1.5 million through milestone-based financing, in exchange for a minority preferred stake that compounds annually. The agreement also includes a redemption mechanism related to the shares.
The transaction marks the latest in a series of minority investments by BrainsWay into leading North American mental health providers as the company seeks to broaden access to Deep Transcranial Magnetic Stimulation (Deep TMS) and other interventional psychiatry solutions.
BrainsWay said the investment strategy enables the company to partner with growth-oriented clinical platforms while remaining focused on advancing its neurostimulation technology and core business operations.
Founded in 2016 by Dr. Abid Nazeer, Hopemark Health provides integrated outpatient psychiatric care and has become known for its work in ketamine-based therapies and evidence-based mental health treatment programs. The company has completed thousands of treatments for patients with mental health and substance use disorders and operates with a multidisciplinary care team that includes psychiatrists, therapists, psychiatric nurse practitioners, physician assistants, and support staff.
BrainsWay is a global neurostimulation company focused on noninvasive treatments for mental health disorders through its proprietary Deep TMS platform. The company currently has FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction, while additional clinical studies are underway across psychiatric, neurological, and addiction-related conditions.
KEY QUOTES:
“Our investment in Hopemark represents another step in our strategy to partner with growth-oriented clinical platforms. These investments are in pursuit of BrainsWay’s broader goal of expanding access to and awareness of advanced interventional psychiatry solutions such as Deep TMS. Our minority stake approach allows BrainsWay to continue to be laser-focused on the continuous advancement of its business and technology.”
Hadar Levy, Chief Executive Officer, BrainsWay
“We are excited to partner with BrainsWay as we continue to expand access to high-quality mental health care. BrainsWay brings not only growth capital, but a deep understanding of interventional psychiatry and operational best practices that will help us scale efficiently and deliver better outcomes for patients. We see this partnership as a meaningful step in accelerating our growth and impact.”
Dr. Abid Nazeer, Chief Executive Officer, Hopemark Health
